doi: 10.2337/dc12-2006 77 RosenstockJRaccahDKornyiLMaffeiLBokaGMiossecPet al
Skin laxity related to the use of GLP-1 receptor agonists is now a primary concern in aesthetic medicine, according to Macrene Alexiades, MD, PhD, FAAD, director and founder of the Dermatology & Laser Center of New York and a Healio Dermatology Peer Perspective Board Member
We have also created an Endobariatric Program, where patients can undergo new minimally invasive bariatric procedures like the endoscopic sleeve gastroplasty
Kidney protection : About 1 in 3 people [archived link] with diabetes also have kidney disease
Take home message Weight-loss injections are designed as additional tools for weight management interventions and shouldnt be considered lifelong medications
16 Matthias Tschp and his team discovered that dual agonists targeting both GLP-1 and GIP receptors (GIPR) are more effective in treating diabetes than those targeting only GLP-1R